CORRECTION: ARCPOINT TO HOST CONFERENCE CALL TO PROVIDE BUSINESS UPDATE AND DISCUSS 2023 Q2 FINANCIAL RESULTS
Greenville, South Carolina, Aug. 14, 2023 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “Company” or “ARCpoint”) a leading US-based...
COVID-19
Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2023
VANCOUVER, British Columbia, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company"),...
Hemostemix Announces Arbitration Award of CAD $315,684 Plus Private Placement
Calgary, Alberta--(Newsfile Corp. - August 14, 2023) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce...
IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology LAWRENCEVILLE, N.J., Aug. 14, 2023...
Allogene Therapeutics Appoints Earl Douglas as General Counsel
Earl Douglas General Counsel, Allogene TherapeuticsSOUTH SAN FRANCISCO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO),...
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update
Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment...
Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024...
Advanced Health Intelligence Ltd Signs Collaboration Agreement with IntelliGen FZ-LLC
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs...
Ainos Reports Second Quarter 2023 Financial Results
Strategic Focus Continues to Pivot from COVID to Pet Health and AI-powered TestingLaunch of VELDONA® Pet Provides New Revenue Stream...
BiondVax Reports Second Quarter Financial Results and Provides Business Update
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on...
Zomedica Announces Record Second Quarter 2023 Financial Results: Revenue up 43% to $6.0 Million; Strong 67% Gross Margin & $142.4 Million in Liquidity
ANN ARBOR, MI / ACCESSWIRE / August 10, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
Applied DNA Reports Third Quarter Fiscal 2023 Financial Results and Provides Corporate Update
Conference Call/Webcast Scheduled for Today at 4:30 PM ETSTONY BROOK, NY / ACCESSWIRE / August 10, 2023 / Applied DNA...
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
Positive Duration of Remission Data Adds to Growing Body of Clinical Evidence Supporting APVO436 for the Treatment of AMLAPVO436 Poised...
Ainos Celebrates First Listing Anniversary on Nasdaq
Ainos reflects upon multiple business milestones following Nasdaq listing, as it diversifies its revenues and advances its product pipelineSAN DIEGO,...
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners
– Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell...
Microbot Medical Strengthens Its Position Among US Interventional Radiologists by Appointing Professor Francois H. Cornelis to Its Scientific Advisory Board
Professor Francois H. Cornelis is a world renown neuro interventional radiologist who specializes in minimally invasive image-guided therapiesHINGHAM, Mass., Aug....
PharmAla Ships MDMA to Mind Medicine Australia and Orygen Institute
PharmAla Continues to Support Clinical Trials as the Foremost Supplier of GMP LaNeo MDMA in AustraliaVANCOUVER, British Columbia, Aug. 10,...
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene®...
Comera Life Sciences Reports Financial Results for Second Quarter 2023 and Recent Business Highlights
– Advanced to final stage of technical evaluation in Comera’s research collaboration with Regeneron, a leading U.S. biotechnology company –...